Corrigendum to “A novel intestinal-restricted FXR agonist” [Bioorg Med Chem Lett 27 (2017) 3386–3390]

Bioorganic & Medicinal Chemistry Letters xxx (2017) xxx–xxx

Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters journal homepage: www.elsevier.com/locate/bmcl

Corrigendum

Corrigendum to ‘‘A novel intestinal-restricted FXR agonist” [Bioorg Med Chem Lett 27 (2017) 3386–3390] Hong Wang a,b,d, Zhou Zhao a,b,d, Jiyu Zhou a,b, Yitong Guo a,b, Guangji Wang a,b, Haiping Hao a,c,⇑, Xiaowei Xu a,b,⇑ a b c

State Key Laboratory of Natural Medicines, China Pharmaceutical University, Tongjiaxiang#24, Nanjing 210009, China Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Tongjiaxiang#24, Nanjing 210009, China School of Pharmacy, China Pharmaceutical University, Tongjiaxiang#24, Nanjing 210009, China

The authors regret that a mistake was made in Table 1. The correct Table 1 appears below. The authors would like to apologise for any inconvenience caused.

Table 1 Transwell results of Fex and Fex-3 in Caco-2 cells within two hours. AP-BL means the velocity of compounds penetrating into the cells, BL-AP is the velocity of compounds going out of the cells **P < 0.01, n = 3.

Fex Fex-3

Con (lM)

Papp AP-BL (10

20 50 20 50

0.35 ± 0.13 0.27 ± 0.15 0.04 ± 0.01 0.02 ± 0.01

7

cm/s)

Papp BL-AP (10

Efflux Ratio 7

cm/s)

0.48 ± 0.06 0.36 ± 0.06 0.03 ± 0.02 0.01 ± 0.01

DOI of original article: https://doi.org/10.1016/j.bmcl.2017.06.003

⇑ Corresponding authors at: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Tongjiaxiang#24, Nanjing 210009, China. d

E-mail addresses: [email protected] (H. Hao), [email protected] (X. Xu). These authors contribute equally to this work.

https://doi.org/10.1016/j.bmcl.2017.10.033 0960-894X/Ó 2017 Elsevier Ltd. All rights reserved.

Please cite this article in press as: Wang H., et al. Bioorg. Med. Chem. Lett. (2017), https://doi.org/10.1016/j.bmcl.2017.10.033

1.35 1.33 0.67 0.57